MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

celecoxib

Search medical newsFind research, conditions and clinical updates
  • Home
  • celecoxib
Celecoxib Cuts Opioid Use Nearly in Half After Throat Surgery—Without Increasing Pain
Posted innews Otorhinolaryngology

Celecoxib Cuts Opioid Use Nearly in Half After Throat Surgery—Without Increasing Pain

Posted by By MedXY 04/02/2026
A retrospective cohort study of 80 patients undergoing tonsillectomy, adenoidectomy, or uvulopalatopharyngoplasty found that adding celecoxib to multimodal analgesia reduced mean opioid consumption by 44%, while maintaining comparable pain control across postoperative days 1, 5, and 10.
Read More
Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib
Posted inHematology-Oncology news Oncology

Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib

Posted by By MedXY 12/07/2025
A post hoc analysis of CALGB (Alliance)/SWOG 80702 shows postoperative ctDNA positivity strongly predicts recurrence and suggests adjuvant celecoxib improves DFS and OS in ctDNA-positive stage III colon cancer.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Beyond Abstinence: Multidisciplinary Approaches Enhance Long-Term Outcomes After Liver Transplantation for Alcohol-Associated Liver Disease
  • Assessing Accuracy and Utility of Melanoma Risk Prediction Models in an Australian Cohort
  • A Minimum Standard Set for Reporting Lymphatic Surgery Outcomes: What the Society of Lymphatic Surgery Consensus Means for Practice
  • Putting People First in ICU Care: ESICM’s 2026 Consensus on Human-Centred Partnership
  • Force Multiplication in Body Contouring: Enhancing Access and Conversion through Advanced Practice Provider Clinics
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top